文献速递创伤与烧伤重症综合管理与镇静镇痛

创伤中的代谢组学与精准医学:领域现状

Metabolomics and Precision Medicine in Trauma: The State of the Field.
PubMed 文献 · Shock · 2018-01-01
一句话结论创伤后并发症伴早期显著代谢改变与炎症反应,现有复苏评估手段可能过于粗糙,代谢组学有望提供细胞及亚细胞层面的诊断与治疗标志物。

创伤是美国45岁以下人群首位死因、全年龄组第三位死因,每年约20万例死亡,医疗花费与生产力损失合计超过6710亿美元,约占美国全部生命损失年的30%。创伤系统发展使多数患者度过初始损伤,却死于并发症;这些并发症以早期显著代谢改变和炎症反应为特征,导致进行性器官衰竭和死亡。早期复苏与手术干预后密切监测以识别并补救治疗失败是良好结局的关键。目前复苏充分性依靠生命体征、床旁超声或每搏量变异等无创方法以及乳酸和碱缺失等实验室终点评估,但这些方法可能过于粗糙,难以反映细胞和亚细胞改变;代谢组学的发展有望将生化标志物用于临床决策。

要点

  • 创伤是美国45岁以下人群首位死因、全年龄组第三位死因,每年约20万例死亡,医疗与生产力损失合计超过6710亿美元。
  • 创伤约占美国全部生命损失年的30%;多数患者度过初始损伤后死于并发症,并发症以早期显著代谢改变和炎症反应为特征,导致进行性器官衰竭和死亡。
  • 早期复苏与手术干预后密切监测以识别并补救治疗失败是良好结局的关键。
  • 目前复苏充分性用生命体征、床旁超声或每搏量变异等无创方法以及乳酸和碱缺失等实验室终点评估,但这些方法可能过于粗糙,难以反映细胞和亚细胞改变。
  • 需要更好的诊断与治疗标志物在细胞和亚细胞层面评估干预充分性、监测反应,并在并发症临床表现出现前指导临床决策;代谢组学在识别和应用生化标志物方面前景广阔。

适用人群与场景

  • 创伤患者,包括度过初始损伤后进入并发症阶段的患者。

处置流程与药物剂量

  • 早期复苏与手术干预后密切监测以识别并补救治疗失败。
  • 目前复苏充分性评估采用生命体征、床旁超声或每搏量变异等无创方法,以及乳酸和碱缺失等实验室终点。

研究设计与关键结果

  • 综述指出创伤后并发症以早期显著代谢改变和炎症反应为特征,导致进行性器官衰竭和死亡。
  • 现有复苏评估方法可能过于粗糙,难以理解创伤患者细胞和亚细胞层面的变化。

证据类型、等级与局限

  • 证据类型:综述。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为需要更好的诊断与治疗标志物,在细胞和亚细胞层面评估干预充分性、监测反应,并在并发症临床表现出现前指导临床决策。
  • 作者认为代谢组学在识别和应用生化标志物用于临床决策方面前景广阔。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Trauma is a major problem in the United States. Mortality from trauma is the number one cause of death under the age of 45 in the United States and is the third leading cause of death for all age groups. There are approximately 200,000 deaths per year due to trauma in the United States at a cost of over $671 billion in combined healthcare costs and lost productivity. Unsurprisingly, trauma accounts for approximately 30% of all life-years lost in the United States. Due to immense development of trauma systems, a large majority of trauma patients survive the injury, but then go on to die from complications arising from the injury. These complications are marked by early and significant metabolic changes accompanied by inflammatory responses that lead to progressive organ failure and, ultimately, death. Early resuscitative and surgical interventions followed by close monitoring to identify and rescue treatment failures are key to successful outcomes. Currently, the adequacy of resuscitation is measured using vital signs, noninvasive methods such as bedside echocardiography or stroke volume variation, and other laboratory endpoints of resuscitation, such as lactate and base deficit. However, these methods may be too crude to understand cellular and subcellular changes that may be occurring in trauma patients. Better diagnostic and therapeutic markers are needed to assess the adequacy of interventions and monitor responses at a cellular and subcellular level and inform clinical decision-making before complications are clinically apparent. The developing field of metabolomics holds great promise in the identification and application of biochemical markers toward the clinical decision-making process.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Jayaraman SP, Anand RJ, DeAntonio JH, et al. Metabolomics and Precision Medicine in Trauma: The State of the Field. Shock. 2018. PMID: 29280924. doi:10.1097/SHK.0000000000001093

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。